Abbott Focuses On Improving Early Diagnosis Of Vascular Disease To Improve Outcomes
Nick West, chief medical officer for Abbott’s vascular business talked to Medtech Insight about Abbott’s efforts to improve the assessment and treatment of vascular disease long before patients need an intervention.
You may also be interested in...
Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.
In this roundup feature focusing on developments in digital health, Medtech Insight highlights interviews with Medtronic, Abbott and Congenica, partnerships and launches, and AI and cybersecurity announcements from November.
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.